






**A****B****C**

Supplementary Fig. 1  
Ohira M et al



Supplementary Fig. 2  
Ohira M et al



Supplementary Fig. 3  
Ohira M et al

## **Supplementary Figure Legends**

### **Supplementary Fig. 1**

Chromatograms for LysoGb<sub>3</sub>(+18) (LCB = t18:0) in FBS of separate lot. **(A)** A chromatogram for LysoGb<sub>3</sub>(+18) in FBS-2. **(B)** A chromatogram for LysoGb<sub>3</sub>(+18) in FBS-3. **(C)** A chromatogram for LysoGb<sub>3</sub>(+18) in FBS-4. Other details were described in Supplementary Table 1.

### **Supplementary Fig. 2**

Accumulation of LysoGb<sub>3</sub> species in human plasma. **(A)** Changes in LysoGb<sub>3</sub>(-28) (LCB = d16:1) in male healthy controls, male Fabry patients, female healthy controls, and female carriers. **(B)** Changes in LysoGb<sub>3</sub>(-2) (LCB = d18:2) in male healthy controls, male Fabry patients, female healthy controls, and female carriers. **(C)** Changes in LysoGb<sub>3</sub>(+16) (LCB = t18:1) in male healthy controls, male Fabry patients, female healthy controls, and female carriers. **(D)** Changes in LysoGb<sub>3</sub>(+18) (LCB = t18:0) in male healthy controls, male Fabry patients, female healthy controls, and female carriers. The number for subjects was: male healthy controls ( $n = 3$ ); male Fabry patients ( $n = 4$ ); female healthy controls ( $n = 5$ ); female carriers ( $n = 2$ ), respectively.

### **Supplementary Fig. 3**

Stability of LysoGb<sub>3</sub> in pooled human plasma under various storage conditions at 37°C. Data were from mean  $\pm$  SD ( $n = 3$ ).

**Supplementary Table 1** Source and origin of country for pooled human plasma and FBS used in this study.

Sample	Supplier (Country)	Cat#	Lot#	Origin of country
Pooled human plasma	Kohjin Bio (Japan)	12250210	BJ9771A	United States
FBS-1	Nichirei (Japan)	171012	9E0808	Australia
FBS-2	GIBCO (US)	10270-106	4240183K	Brazil
FBS-3	GIBCO (US)	10270-106	4240584K	Brazil
FBS-4	Biowest (France)	S1820-500	S18092S1530	Columbia

**Supplementary Table 2** MS1, MS2, cone energy and collision energy for the quantification of LysoGb<sub>3</sub> and its analogues in human plasma using LC-MS/MS<sup>a</sup>.

	MS1 (m/z)	MS2 (m/z)	Cone (V)	Collision (V)	Confirmed/Sug- gested compound	Putative fragmentation for MS2
LysoGb <sub>3</sub>	786.4	282.2	20	40	LysoGb <sub>3</sub> (d18:1)[LCB-H <sub>2</sub> O+H] <sup>+</sup>	
LysoGb <sub>3</sub> -Gly (IS)	843.4	264.2	30	45	LysoGb <sub>3</sub> (d18:1-[LCB-2×H <sub>2</sub> O+H] <sup>+</sup> <i>N</i> -Gly)	
LysoGb <sub>3</sub> (-28)	758.4	254.3	20	40	LysoGb <sub>3</sub> (d16:1)[LCB-H <sub>2</sub> O+H] <sup>+</sup>	
LysoGb <sub>3</sub> (-12)	774.4	252.3	20	40	LysoGb <sub>3</sub> (t16:1) [LCB-3×H <sub>2</sub> O+H] <sup>+</sup>	
LysoGb <sub>3</sub> (-2)	784.4	280.3	20	40	LysoGb <sub>3</sub> (d18:2)[LCB-H <sub>2</sub> O+H] <sup>+</sup>	
LysoGb <sub>3</sub> (+16)	802.4	280.3	20	40	LysoGb <sub>3</sub> (t18:1) [LCB-2×H <sub>2</sub> O+H] <sup>+</sup>	
LysoGb <sub>3</sub> (+18)	804.5	318.3	20	40	LysoGb <sub>3</sub> (t18:0) [LCB+H] <sup>+</sup>	
LysoGb <sub>3</sub> (+34)	820.5	334.3	20	40	Not identified	Not identified
LysoGb <sub>3</sub> (+50)	836.5	350.2	20	40	Not identified	Not identified

<sup>a</sup>Adopted from Boutin M and Auray-Blais C, Anal. Chem. (2014) 86(7):3476-83.

IS, internal standard.

**Supplementary Table 3** MRM table for LysoGb<sub>3</sub> species with C14-C26 LCB.

Category	Species	MS1			MS2		
		[M+H] <sup>+</sup>	[LCB+H] <sup>+</sup>	[LCB-H <sub>2</sub> O+H] <sup>+</sup>	[LCB-2×H <sub>2</sub> O+H] <sup>+</sup>	[LCB-3×H <sub>2</sub> O+H] <sup>+</sup>	[LCB-4×H <sub>2</sub> O+H] <sup>+</sup>
dX:0	d14:0	732.4	246.2	228.2	210.2	192.2	NA
	d15:0	746.4	260.2	242.2	224.2	206.2	NA
	d16:0	760.4	274.2	256.2	238.2	220.2	NA
	d17:0	774.4	288.2	270.2	252.2	234.2	NA
	d18:0	788.4	302.2	284.2	266.2	248.2	NA
	d19:0	802.4	316.2	298.2	280.2	262.2	NA
	d20:0	816.4	330.2	312.2	294.2	276.2	NA
	d21:0	830.4	344.2	326.2	308.2	290.2	NA
	d22:0	844.4	358.2	340.2	322.2	304.2	NA
	d23:0	858.4	372.2	354.2	336.2	318.2	NA
	d24:0	872.4	386.2	368.2	350.2	332.2	NA
	d25:0	886.4	400.2	382.2	364.2	346.2	NA
	d26:0	900.4	414.2	396.2	378.2	360.2	NA
dX:1	d14:1	730.4	244.2	226.2	208.2	190.2	NA
	d15:1	744.4	258.2	240.2	222.2	204.2	NA
	d16:1	758.4	272.2	254.2	236.2	218.2	NA
	d17:1	772.4	286.2	268.2	250.2	232.2	NA
	d18:1	786.4	300.2	282.2	264.2	246.2	NA
	d19:1	800.4	314.2	296.2	278.2	260.2	NA
	d20:1	814.4	328.2	310.2	292.2	274.2	NA
	d21:1	828.4	342.2	324.2	306.2	288.2	NA
	d22:1	842.4	356.2	338.2	320.2	302.2	NA
	d23:1	856.4	370.2	352.2	334.2	316.2	NA
	d24:1	870.4	384.2	366.2	348.2	330.2	NA
	d25:1	884.4	398.2	380.2	362.2	344.2	NA
	d26:1	898.4	412.2	394.2	376.2	358.2	NA
dX:2	d14:2	728.4	242.2	224.2	206.2	188.2	NA

d15:2	742.4	256.2	238.2	220.2	202.2	NA
d16:2	756.4	270.2	252.2	234.2	216.2	NA
d17:2	770.4	284.2	266.2	248.2	230.2	NA
d18:2	784.4	298.2	280.2	262.2	244.2	NA
d19:2	798.4	312.2	294.2	276.2	258.2	NA
d20:2	812.4	326.2	308.2	290.2	272.2	NA
d21:2	826.4	340.2	322.2	304.2	286.2	NA
d22:2	840.4	354.2	336.2	318.2	300.2	NA
d23:2	854.4	368.2	350.2	332.2	314.2	NA
d24:2	868.4	382.2	364.2	346.2	328.2	NA
d25:2	882.4	396.2	378.2	360.2	342.2	NA
d26:2	896.4	410.2	392.2	374.2	356.2	NA
<hr/>						
dX:3	d14:3	726.4	240.2	222.2	204.2	186.2
	d15:3	740.4	254.2	236.2	218.2	200.2
	d16:3	754.4	268.2	250.2	232.2	214.2
	d17:3	768.4	282.2	264.2	246.2	228.2
	d18:3	782.4	296.2	278.2	260.2	242.2
	d19:3	796.4	310.2	292.2	274.2	256.2
	d20:3	810.4	324.2	306.2	288.2	270.2
	d21:3	824.4	338.2	320.2	302.2	284.2
	d22:3	838.4	352.2	334.2	316.2	298.2
	d23:3	852.4	366.2	348.2	330.2	312.2
	d24:3	866.4	380.2	362.2	344.2	326.2
	d25:3	880.4	394.2	376.2	358.2	340.2
	d26:3	894.4	408.2	390.2	372.2	354.2
<hr/>						
tX:0	t14:0	748.4	262.2	244.2	226.2	208.2
	t15:0	762.4	276.2	258.2	240.2	222.2
	t16:0	776.4	290.2	272.2	254.2	236.2
	t17:0	790.4	304.2	286.2	268.2	250.2
						232.2

t18:0	804.4	318.2	300.2	282.2	264.2	246.2
t19:0	818.4	332.2	314.2	296.2	278.2	260.2
t20:0	832.4	346.2	328.2	310.2	292.2	274.2
t21:0	846.4	360.2	342.2	324.2	306.2	288.2
t22:0	860.4	374.2	356.2	338.2	320.2	302.2
t23:0	874.4	388.2	370.2	352.2	334.2	316.2
t24:0	888.4	402.2	384.2	366.2	348.2	330.2
t25:0	902.4	416.2	398.2	380.2	362.2	344.2
t26:0	916.4	430.2	412.2	394.2	376.2	358.2
tX:1	t14:1	746.4	260.2	242.2	224.2	206.2
	t15:1	760.4	274.2	256.2	238.2	220.2
	t16:1	774.4	288.2	270.2	252.2	234.2
	t17:1	788.4	302.2	284.2	266.2	248.2
	t18:1	802.4	316.2	298.2	280.2	262.2
	t19:1	816.4	330.2	312.2	294.2	276.2
	t20:1	830.4	344.2	326.2	308.2	290.2
	t21:1	844.4	358.2	340.2	322.2	304.2
	t22:1	858.4	372.2	354.2	336.2	318.2
	t23:1	872.4	386.2	368.2	350.2	332.2
	t24:1	886.4	400.2	382.2	364.2	346.2
	t25:1	900.4	414.2	396.2	378.2	360.2
	t26:1	914.4	428.2	410.2	392.2	374.2

d, dihydroxy; t, trihydroxy; NA, not applicable; X, carbon number.

**Supplementary Table 4** Instrument parameters for the quantification of LysoGb<sub>3</sub> and other compounds in this study using reversed-phase chromatography.

Instrument	Xevo TQ-S micro (Waters)
MS parameter	
Interface	ESI
Polarity	Positive
Capillary voltage	2.5 kV
Source temperature	150°C
Desolvation temperature	450°C
Flow rate of cone gas	50 L/h
Flow rate of desolvation gas	800 L/h
Analyzing mode	Multiple reaction monitoring
Dwell time	0.05 s
Data format	Centroid
UPLC parameter	
Column	UPLC BEH C18 (50 mm) Internal diameter: 2.1 μm Particle diameter: 1.7 μm
Column temperature	40°C
Weak wash solvent	0.2% formic acid in water/acetonitrile (50/50)
Strong wash solvent	0.2% formic acid in methanol
Mobile phase A	0.2% formic acid in water/acetonitrile (95/5)
Mobile phase B	0.2% formic acid in acetonitrile
Gradient (%B)	
LysoGb <sub>3</sub> separation	0.0 - 1.0 min: 0% 1.0 - 3.0 min: 0 - 35% 3.0 - 5.5 min: 35 - 50% 5.51 - 7.0 min: 90% 7.01 - 9.0 min: 0%
Ceramide separation	0.0 - 0.5 min: 90% 0.5 - 6.0 min: 90-100% 6.0 - 10 min: 100% 10.1 - 12 min: 90%
Flow rate	0.5 mL/min
Injection volume	5 μL
Injection mode	Partial loop-fill method
Autosampler temperature	10°C

ESI, electrospray ionization.

**Supplementary Table 5** MRM table for ceramide and Gb<sub>3</sub>

Compound name	N-acyl group	LCB	MS1	MS2	Cone (V)	Collision (V)
			[M+H] <sup>+</sup>	[LCB-2×H <sub>2</sub> O+H] <sup>+</sup>		
Ceramide	C14:0	d18:1	511.0	264.2	20	20
	C15:0	d18:1	525.0	264.2	20	20
	C16:0	d18:1	539.0	264.2	20	20
	C17:0 (Internal standard)	d18:1	553.0	264.2	20	20
	C18:0	d18:1	567.0	264.2	20	20
	C19:0	d18:1	581.0	264.2	20	20
	C20:0	d18:1	595.0	264.2	20	20
	C21:0	d18:1	609.0	264.2	20	20
	C22:0	d18:1	623.0	264.2	20	20
	C23:0	d18:1	637.0	264.2	20	20
	C24:0	d18:1	651.0	264.2	20	20
	C25:0	d18:1	665.0	264.2	20	20
	C26:0	d18:1	679.0	264.2	20	20
Gb <sub>3</sub>	C16:0	d18:1	1025.0	264.2	20	20

**Supplementary Table 6** MRM table for sphinganine and sphingosine.

Compound name	LCB	MS1	MS2	Cone	Collision
		[M+H] <sup>+</sup>	[LCB-H <sub>2</sub> O+H] <sup>+</sup>	(V)	(V)
Sphinganine	d18:0	298.2	280.2	20	10
Sphingosine	d18:1	300.2	282.2	20	10